Overview

The DENOCHARCOT Trial

Status:
Recruiting

Trial end date:
2026-10-01

Target enrollment:

Participant gender:

Summary

The aim of the present trial is to assess the efficacy of treatment of acute Charcot foot in diabetes patients with Prolia® on clinical relevant Outcomes in a randomized, double blind, placebo-controlled trial.

Phase:

Phase 3

Details

Lead Sponsor:

Ole Lander Svendsen

Treatments:

Denosumab